retatrutide fda approval timeline 2025 Tirzepatide vs. Retatrutide Peptide for Weight Loss,

Community protocols use 250mcg 3x/week -- far below the 2.4mg clinical dose

AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Sanofi and Hypera S.A

Travel-friendly & TSA-compliant Approved for air travel in carry-on and checked luggage

The association was consistent across alcohol- and non-alcohol-related overdoses and was even stronger among patients not receiving traditional addiction-treatment medications

The growing popularity of GLP-1 weight-loss drugs is reshaping the yogurt market, as consumers increasingly seek protein-packed snacks.

GLP-1 drugs shown cost-effective for knee osteoarthritis and obesity A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide